Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial for tough bone cancer halted early

NCT ID NCT03514407

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called INCB059872 in 25 people with Ewing sarcoma that had returned or stopped responding to standard treatments. The goal was to check the drug's safety and see if it could shrink tumors. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
INCB059872 (an experimental drug taken by mouth every other day)
What this could lead to
If it works, this could point toward a new treatment option for people with Ewing sarcoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 25 participants, and it was terminated early, so results are limited. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

25 people

The number who actually took part.

Started

Jun 2018

Finished

Jun 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies. * Must not be a candidate for potentially curative therapy or standard-of-care approved therapy. * Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology. * Eastern Cooperative Oncology Group performance status 0 to 2. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug. * Must have recovered (≤ Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve. * Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval. * Laboratory values outside the protocol-defined range at screening. * History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed Ewing sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed Ewing sarcoma

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Istituto Ortopedico Rizzoli

    Bologna, 40136, Italy

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida, 32224, United States

  • Ospedale Pediatrico Bambino Gesu IRCCS

    Rome, 00146, Italy

  • Policlinico Sant'orsola-Malpighi

    Bologna, 40138, Italy

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • UCLA Jonsson Comprehensive Cancer

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.